Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several key prescribing-label elements are missing or not supported by the provided label excerpts, including FDA-approved indication/adjunct language, administration/dosing regimen (once daily), and multiple safety-frequency/comparative assertions. Some safety concepts are supported (lactic acidosis risk, volume depletion, genitourinary infections, eGFR initiation/contraindication thresholds).
Category Scores
Accurate Statements
Synjardy XR contains empagliflozin.
11 DESCRIPTION (SYNJARDY and SYNJARDY XR tablets for oral use contain: empagliflozin and metformin HCl)
Synjardy XR contains metformin hydrochloride.
11 DESCRIPTION (SYNJARDY and SYNJARDY XR tablets for oral use contain: empagliflozin and metformin HCl)
Metformin can be associated with lactic acidosis risk in specific settings.
5 WARNING: LACTIC ACIDOSIS (risk factors provided; management described)
Empagliflozin can be associated with rare genitourinary complications.
5.4 Genitourinary Infections... Necrotizing fasciitis of the perineum (Fournier's gangrene) (rare life-threatening infection)
Kidney function affects whether someone can use Synjardy XR.
2.4 Dosage Recommendations in Patients with Renal Impairment (initiation not recommended eGFR <45; contraindicated eGFR <30) and 4 CONTRAINDICATIONS (eGFR <30)
Empagliflozin helps the kidneys remove glucose through urine.
5.4 (Empagliflozin increases urinary glucose excretion)
Unsupported Statements
Synjardy XR is used to improve blood sugar control in adults with type 2 diabetes.
The provided excerpts do not include the FDA-approved Indications/Usage text.
Synjardy XR is used as an adjunct to diet and exercise.
The provided excerpts do not include the FDA-approved Indications/Usage text.
Synjardy XR is taken by mouth once daily.
The provided label excerpts do not include a once-daily dosing regimen.
Synjardy XR is once daily because it is an extended-release formulation.
The provided label excerpts do not provide once-daily rationale or regimen tied to XR formulation.
The exact dose of Synjardy XR depends on prior metformin/empagliflozin exposure.
No provided label excerpt addresses dosing based on prior exposure.
Empagliflozin has medication-associated risk during periods of reduced intake.
No provided label excerpt mentions reduced intake/sick-day type guidance.
Commonly reported side effects include gastrointestinal effects.
The provided excerpts do not include adverse reaction frequency statements.
Gastrointestinal effects are more often related to metformin.
The provided excerpts do not compare attribution or relative frequency between components.
Commonly reported side effects include increased urination.
The provided excerpts support urinary glucose excretion and urine volume/frequency in a specific diuretic interaction context, but do not provide a general 'commonly reported' frequency statement.
Synjardy XR can be available in different strengths with different mg amounts of metformin and empagliflozin.
No provided label excerpt lists product strengths or mg combinations.
Commonly reported side effects include genital yeast infections.
The provided excerpts support genitourinary mycotic infections/risk but do not state 'commonly reported' frequency.
Contradictions
Important Omissions
FDA-approved Indications/Usage statement(s) (including adult population and adjunct-to-diet/exercise wording).
Importance:
High
Full dosage and administration instructions, including confirmed dosing frequency (e.g., once daily), titration, and tablet-specific administration details.
Importance:
High
Contraindications beyond renal function and general hypersensitivity/metabolic acidosis (if the AI response intended to cover them).
Importance:
Moderate
Adverse reactions frequency section(s) or list of 'common' adverse reactions (to support 'commonly reported' claims).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or unverifiable claims about dosing regimen (once daily), indications/adjunct wording, and comparative 'more often/commonly reported' adverse reaction frequency could mislead patient counseling or use; however, several safety-critical concepts (lactic acidosis risk, volume depletion/renal function considerations, genitourinary severe infection warning) are supported by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Key prescribing-label elements (FDA-approved indications/adjunct-to-diet/exercise and confirmed dosing regimen/administration) are not supported by the provided label excerpts; several adverse-effect 'commonly reported' and comparative frequency/attribution statements are also not supported.
Suggested Improvement
Limit claims to what is explicitly supported in the provided label excerpts (e.g., ingredient composition, renal eGFR initiation/contraindication thresholds, lactic acidosis warning, volume depletion, and genitourinary infection risk) and remove or qualify unverifiable administration/dosing-frequency, indications, and frequency/comparative adverse reaction statements unless the corresponding FDA-approved sections are provided.